At this year’s Fierce Biotech Summit in Boston, we caught up with leaders in the biotech industry who have been recognized as past Fierce 15 honorees. 

These private biotechs have made significant contributions to their field, and their groundbreaking work is shaping the industry's future.

Fierce Biotech’s Gabrielle Masson sat down with Liang Schweizer, Ph.D. founder, chairperson and CEO of HiFiBiO Therapeutics; Adam Friedman, M.D., Ph.D., CEO of Scorpion Therapeutics; and Debanjan Ray CEO of Synthekine. 

In this week’s episode of “The Top Line,” these leaders share their insights, experiences, and visions for the evolving biotech landscape.

To learn more about the topics in this episode: 


Introducing Fierce Biotech's 2024 Fierce 15


Scorpion snaps up $150M in series C funds to widen clinical plans for cancer pipeline


Synthekine hopes new IL-2 will be the high-alpha in a beta class

At this year’s Fierce Biotech Summit in Boston, we caught up with leaders in the biotech industry who have been recognized as past Fierce 15 honorees. 
These private biotechs have made significant contributions to their field, and their groundbreaking work is shaping the industry's future.
Fierce Biotech’s Gabrielle Masson sat down with Liang Schweizer, Ph.D. founder, chairperson and CEO of HiFiBiO Therapeutics; Adam Friedman, M.D., Ph.D., CEO of Scorpion Therapeutics; and Debanjan Ray CEO of Synthekine. 
In this week’s episode of “The Top Line,” these leaders share their insights, experiences, and visions for the evolving biotech landscape.
To learn more about the topics in this episode: 
<ul>
<li>
<a href="https://www.fiercebiotech.com/special-reports/introducing-fierce-biotechs-2024-fierce-15">Introducing Fierce Biotech's 2024 Fierce 15</a>
</li>
<li>
<a href="https://www.fiercebiotech.com/biotech/scorpion-snaps-150m-series-c-funds-widen-clinical-plans-cancer-pipeline">Scorpion snaps up $150M in series C funds to widen clinical plans for cancer pipeline</a>
</li>
<li>
<a href="https://www.fiercebiotech.com/biotech/aacr-synthekine-hopes-new-il-2-will-be-high-alpha-beta-class">Synthekine hopes new IL-2 will be the high-alpha in a beta class</a> 
</li>
</ul>

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Where are they now? Catching up with past Fierce 15 honorees

In this week’s episode of "The Top Line," we bring you a special conversation from earlier this month at our New York City gala, where we celebrated this year’s Fierce 50 honorees.

On stage, five extraordinary leaders shared their insights, experiences, and bold ideas shaping the future of healthcare and beyond. These honorees represent the five categories of this year’s Fierce 50: health equity, innovation, social impact, breakthroughs and patient advocacy.

Each honoree brings powerful insights and inspiring stories to the table. From reimagining maternal healthcare and addressing antibiotic resistance to translating public health science, transforming healthcare with AI, and tackling rural health challenges, this panel highlights innovation and disruption at its finest.

To learn more about the topics in this episode: 
Fierce 50 of 2024
Fierce 50 of 2024 - Innovation Honorees
Fierce 50 of 2024 - Health Equity Honorees
Fierce 50 of 2024 - Social Impact Honorees
Fierce 50 of 2024 - Breakthroughs Honorees 
Fierce 50 of 2024 - Patient Advocacy Honorees 

In this week&rsquo;s episode of "The Top Line," we bring you a special conversation from earlier this month at our New York City gala, where we celebrated this year&rsquo;s Fierce 50 honorees.
On stage, five extraordinary leaders shared their insights, experiences, and bold ideas shaping the future of healthcare and beyond. These honorees represent the five categories of this year&rsquo;s Fierce 50: health equity, innovation, social impact, breakthroughs and patient advocacy.
Each honoree brings powerful insights and inspiring stories to the table. From reimagining maternal healthcare and addressing antibiotic resistance to translating public health science, transforming healthcare with AI, and tackling rural health challenges, this panel highlights innovation and disruption at its finest.
To learn more about the topics in this episode:&nbsp;
<ul>
<li><a href="https://www.fiercepharma.com/collection/fierce-50-2024">Fierce 50 of 2024</a></li>
<li><a href="https://www.fiercepharma.com/book/innovation">Fierce 50 of 2024 - Innovation Honorees</a></li>
<li><a href="https://www.fiercepharma.com/book/health-equity">Fierce 50 of 2024 - Health Equity Honorees</a></li>
<li><a href="https://www.fiercepharma.com/book/social-impact">Fierce 50 of 2024 - Social Impact Honorees</a></li>
<li><a href="https://www.fiercepharma.com/book/breakthroughs">Fierce 50 of 2024 - Breakthroughs Honorees&nbsp;</a></li>
<li><a href="https://www.fiercepharma.com/book/patient-advocacy">Fierce 50 of 2024 - Patient Advocacy Honorees&nbsp;</a></li>
</ul>

Fierce 50 honorees look ahead: AI, rural health, antibiotic resistance, maternal care and more

GLP-1 agonists have taken the pharma world by storm, and Novo Nordisk has been at the forefront of it all with its blockbuster drug semaglutide, which it sells as Ozempic, Wegovy and Rybelsus. Semaglutide and other GLP-1s have gained widespread popularity as treatments for Type 2 diabetes and obesity, and it doesn’t stop there—they’re currently being tested in a wide variety of additional therapeutic areas and in new dosages and forms.

In this week’s episode of “The Top Line,” Fierce’s James Waldron talked to Marcus Schindler, Novo’s chief scientific officer and executive VP of research and early development, about what’s next for GLP-1s and what else is top of mind at the Danish pharma.

To learn more about the topics in this episode:
Novo Nordisk hails ‘remarkable’ weight loss result for dual-acting oral drug in early trial
Novo obesity prospect linked to ‘mild to moderate neuropsychiatric side effects’ in phase 2
Novo Nordisk axes once-monthly GLP-1/GIP agonist and MASH prospect
Another day, another win for Novo in obesity, as early oral med appears to beat Wegovy

GLP-1 agonists have taken the pharma world by storm, and Novo Nordisk has been at the forefront of it all with its blockbuster drug semaglutide, which it sells as Ozempic, Wegovy and Rybelsus. Semaglutide and other GLP-1s have gained widespread popularity as treatments for Type 2 diabetes and obesity, and it doesn&rsquo;t stop there&mdash;they&rsquo;re currently being tested in a wide variety of additional therapeutic areas and in new dosages and forms.
In this week&rsquo;s episode of &ldquo;The Top Line,&rdquo; Fierce&rsquo;s James Waldron talked to Marcus Schindler, Novo&rsquo;s chief scientific officer and executive VP of research and early development, about what&rsquo;s next for GLP-1s and what else is top of mind at the Danish pharma.
To learn more about the topics in this episode:
<ul>
<li><a href="https://www.fiercebiotech.com/biotech/novo-nordisk-hails-remarkable-weight-loss-oral-glp-1-drug">Novo Nordisk hails &lsquo;remarkable&rsquo; weight loss result for dual-acting oral drug in early trial</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/novos-obesity-drug-linked-mild-moderate-neuropsychiatric-side-effects-phase-2">Novo obesity prospect linked to &lsquo;mild to moderate neuropsychiatric side effects&rsquo; in phase 2</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/novo-nordisk-axes-once-monthly-glp-1gip-agonist-mash-prospect">Novo Nordisk axes once-monthly GLP-1/GIP agonist and MASH prospect</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/another-day-another-win-novo-obesity-early-oral-med-beats-wegovy">Another day, another win for Novo in obesity, as early oral med appears to beat Wegovy</a></li>
</ul>

Novo Nordisk’s chief scientific officer looks to the future of GLP-1s

After a promising start to the year, the biotech IPO market picked up steam again late this summer, with notable offerings from companies like Upstream, Septerna and BioAge. But what does this mean for the sector? Is market enthusiasm truly returning, or are we just seeing a temporary rebound?

To unpack these questions and look ahead to 2025, Fierce Biotech’s James Waldron chatted with Adam Farlow, Global Chair of Baker McKenzie’s Capital Markets Practice Group.  

To learn more about the topics in this episode: 
Septerna's $288M IPO is another sign of the market warming to biotech investment
BioAge brings in almost $200M from IPO as obesity biotech joins Nasdaq
Upstream swells IPO to $255M as it prepares to join Nasdaq along with CAMP4
Kairos goes public with $6M IPO to fund trials of lead cancer drug

After a promising start to the year, the biotech IPO market picked up steam again late this summer, with notable offerings from companies like Upstream, Septerna and BioAge. But what does this mean for the sector? Is market enthusiasm truly returning, or are we just seeing a temporary rebound?
To unpack these questions and look ahead to 2025, Fierce Biotech’s James Waldron chatted with Adam Farlow, Global Chair of Baker McKenzie’s Capital Markets Practice Group.  
To learn more about the topics in this episode: 
<ul>
<li><a href="https://www.fiercebiotech.com/biotech/septernas-288m-ipo-another-sign-market-warming-biotech-investment">Septerna's $288M IPO is another sign of the market warming to biotech investment</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/bioage-brings-almost-200m-ipo-obesity-biotech-joins-nasdaq">BioAge brings in almost $200M from IPO as obesity biotech joins Nasdaq</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/upstream-swells-ipo-255m-it-prepares-join-nasdaq-along-camp4">Upstream swells IPO to $255M as it prepares to join Nasdaq along with CAMP4</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/kairos-goes-public-6m-ipo-fund-trials-lead-cancer-drug">Kairos goes public with $6M IPO to fund trials of lead cancer drug</a></li>
</ul>

Where are they now? Catching up with past Fierce 15 honorees

In 1 playlist(s)

The Top Line

Social links

Follow podcast

Recent clips